Patents Assigned to CLS Therapeutics Limited
-
Patent number: 11905522Abstract: The invention relates to the liver-specific delivery and/or expression of an enzyme which has a deoxyribonuclease (DNase) activity for enhanced clearance of cell free DNA (cfDNA) accumulated in hepatic porto-sinusoidal circulation and the use of such liver-specific delivery and/or expression for treatment of various diseases and conditions, including cancer and neurodegeneration.Type: GrantFiled: January 15, 2019Date of Patent: February 20, 2024Assignee: CLS THERAPEUTICS LIMITEDInventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
-
Publication number: 20240050476Abstract: The invention relates to methods for treatment of cancers utilizing a combination of a deoxyribonuclease enzyme and adoptive cell immunotherapy comprising cells expressing a chimeric antigen receptor (CAR) or a T cell receptor (TCR). In particular embodiments, the deoxyribonuclease enzyme can be given parenterally or encoded by a vector or secreted by a cell comprising TCR or CAR.Type: ApplicationFiled: January 7, 2022Publication date: February 15, 2024Applicant: CLS THERAPEUTICS LIMITEDInventors: Dmitry Dmitrievich GENKIN, Georgy Viktorovich TETS, Viktor Veniaminovich TETS, Alexey Vyacheslavovich STEPANOV
-
Patent number: 11701410Abstract: The invention relates to the use of deoxyribonuclease (DNase) enzyme for inhibiting progression and for prevention and treatment of neurodegeneration.Type: GrantFiled: May 11, 2016Date of Patent: July 18, 2023Assignee: CLS THERAPEUTICS LIMITEDInventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
-
Publication number: 20220241394Abstract: The invention relates to the nervous system-specific delivery and/or expression of an enzyme which has a deoxyribonuclease (DNase) activity for enhanced clearance of microbial and viral cell free DNA (cfDNA) accumulated in cerebrospinal fluid (CSF), brain and other parts of nervous system, with the use of such nervous-system specific delivery and/or expression for treatment of various diseases associated with protein misfolding.Type: ApplicationFiled: July 10, 2020Publication date: August 4, 2022Applicant: CLS THERAPEUTICS LIMITEDInventors: Dmitry Dmitrievich GENKIN, Georgy Viktorovich TETS, Viktor Veniaminovich TETS
-
Publication number: 20200188493Abstract: The invention relates to the use of a deoxyribonuclease (DNase) enzyme for prevention or amelioration of toxicity associated with various cytostatic and/or cytotoxic chemotherapeutic compounds and radiation therapy.Type: ApplicationFiled: February 20, 2020Publication date: June 18, 2020Applicant: CLS Therapeutics LimitedInventors: Dmitry Dmitrievich GENKIN, Georgy Viktorovich TETS, Viktor Veniaminovich TETS
-
Patent number: 10617743Abstract: The invention relates to the use of a deoxyribonuclease (DNase) enzyme for prevention or amelioration of toxicity associated with various cytostatic and/or cytotoxic chemotherapeutic compounds and radiation therapy.Type: GrantFiled: June 19, 2015Date of Patent: April 14, 2020Assignee: CLS THERAPEUTICS LIMITEDInventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
-
Publication number: 20190241908Abstract: The invention relates to the liver-specific delivery and/or expression of an enzyme which has a deoxyribonuclease (DNase) activity for enhanced clearance of cell free DNA (cfDNA) accumulated in hepatic porto-sinusoidal circulation and the use of such liver-specific delivery and/or expression for treatment of various diseases and conditions, including cancer and neurodegeneration.Type: ApplicationFiled: January 15, 2019Publication date: August 8, 2019Applicant: CLS THERAPEUTICS LIMITEDInventors: Dmitry Dmitrievich GENKIN, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
-
Publication number: 20180071370Abstract: The invention relates to the use of a deoxyribonuclease (DNase) enzyme for prevention or amelioration of toxicity associated with various cytostatic and/or cytotoxic chemotherapeutic compounds and radiation therapy.Type: ApplicationFiled: June 19, 2015Publication date: March 15, 2018Applicant: CLS Therapeutics LimitedInventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
-
Patent number: 9845461Abstract: A method to treat cancer and other malignant diseases, said method comprising parenterally administering an agent which destroys blood extracellular DNA into the systemic circulation of a cancer patient to slow down cancer growth. The agent is embodied in the form of a DNase enzyme and, more particularly, as a DNase I enzyme. Doses from 50,000-250,000,000 Kunitz units/day are administered for 5-360 days.Type: GrantFiled: January 5, 2016Date of Patent: December 19, 2017Assignee: CLS Therapeutics LimitedInventors: Dmitry Dmitrievich Genkin, Viktor Veniaminovich Tets, Georgy Viktorovich Tets
-
Patent number: 9770492Abstract: The invention is directed to treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient.Type: GrantFiled: May 18, 2016Date of Patent: September 26, 2017Assignee: CLS Therapeutics LimitedInventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
-
Publication number: 20170100463Abstract: The invention relates to the use of a deoxyribonuclease (DNase) enzyme for prevention or amelioration of toxicity associated with various cytostatic and/or cytotoxic chemotherapeutic compounds and radiation therapy.Type: ApplicationFiled: December 19, 2016Publication date: April 13, 2017Applicant: CLS Therapeutics LimitedInventors: Dmitry Dmitrievich GENKIN, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
-
Publication number: 20170056482Abstract: The invention is directed to treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient.Type: ApplicationFiled: October 6, 2016Publication date: March 2, 2017Applicant: CLS Therapeutics LimitedInventors: Dmitry Dmitrievich GENKIN, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
-
Publication number: 20160303204Abstract: The invention is directed to treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient.Type: ApplicationFiled: May 18, 2016Publication date: October 20, 2016Applicant: CLS Therapeutics LimitedInventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
-
Patent number: 9463223Abstract: The invention is directed to treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient.Type: GrantFiled: June 19, 2014Date of Patent: October 11, 2016Assignee: CLS Therapeutics LimitedInventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
-
Publication number: 20160130570Abstract: A method to treat cancer and other malignant diseases, said method comprising parenterally administering an agent which destroys blood extracellular DNA into the systemic circulation of a cancer patient to slow down cancer growth. The agent is embodied in the form of a DNase enzyme and, more particularly, as a DNase I enzyme. Doses from 50,000-250,000,000 Kunitz units/day are administered for 5-360 days.Type: ApplicationFiled: January 5, 2016Publication date: May 12, 2016Applicant: CLS Therapeutics LimitedInventors: Dmitry Dmitrievich Genkin, Viktor Veniaminovich Tets, Georgy Viktorovich Tets
-
Patent number: 9248166Abstract: A method to treat cancer and other malignant diseases, said method comprising parenterally administering an agent which destroys blood extracellular DNA into the systemic circulation of a cancer patient to slow down cancer growth. The agent is embodied in the form of a DNase enzyme and, more particularly, as a DNase I enzyme. Doses from 50,000-250,000,000 Kunitz units/day are administered for 5-360 days.Type: GrantFiled: March 10, 2014Date of Patent: February 2, 2016Assignee: CLS THERAPEUTICS LIMITEDInventors: Dmitry Dmitrievich Genkin, Viktor Veniaminovich Tets, Georgy Viktorovich Tets
-
Patent number: 9072733Abstract: The invention is directed to a treatment of systemic bacterial, fungal and protozoan infections. The inventive method comprises introducing a DNase enzyme into a circulating blood system of a patient diagnosed with systemic infection caused by bacteria, fungi or protozoa, wherein said DNase enzyme destroys extracellular DNA in said blood of said patient, said DNase enzyme being administered in doses and regimens which are sufficient to decrease the average molecular weight of circulating extracellular blood DNA in the blood of said patient.Type: GrantFiled: March 6, 2013Date of Patent: July 7, 2015Assignee: CLS THERAPEUTICS LIMITEDInventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
-
Publication number: 20150110769Abstract: The present invention provides a method for retarding unhealthy manifestations brought by ageing of human beings (in particular, but not limited to the reduction of sexual activity and fertility, climax, changes in glucose tolerance, reduction of cognitive and mnestic functions, reduction of stress resistance, development of organ and tissue sclerosis). According to the invention this task is solved by administration into the blood circulation of an agent which inactivates extracellular blood plasma DNA e.g. a DNase enzyme.Type: ApplicationFiled: December 22, 2014Publication date: April 23, 2015Applicant: CLS THERAPEUTICS LIMITEDInventors: Dmitry Dmitrievich Genkin, Viktor Veniaminovich Tets, Georgy Viktorovich Tets
-
Publication number: 20150010523Abstract: The invention is directed to treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient.Type: ApplicationFiled: June 19, 2014Publication date: January 8, 2015Applicant: CLS THERAPEUTICS LIMITEDInventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
-
Patent number: 8916151Abstract: The present invention provides a method for retarding unhealthy manifestations brought by ageing of human beings (in particular, but not limited to the reduction of sexual activity and fertility, climax, changes in glucose tolerance, reduction of cognitive and mnestic functions, reduction of stress resistance, development of organ and tissue sclerosis). According to the invention this task is solved by administration into the blood circulation of an agent which inactivates extracellular blood plasma DNA.Type: GrantFiled: April 25, 2005Date of Patent: December 23, 2014Assignee: CLS Therapeutics LimitedInventors: Dmitry Dmitrievich Genkin, Viktor Veniaminovich Tets, Georgy Viktorovich Tets